Beijing Beilu Pharmaceutical (300016.SZ) obtained the registration certificate for the drug Pioglitazone Metformin Tablets.
Beilu Pharmaceutical (300016.SZ) announced that the company has received the "Drug Registration Certificate" issued by the National Medical Products Administration for pioglitazone metformin tablets (15mg/500mg). This product is suitable for type 2 diabetes patients who are currently being treated with pioglitazone hydrochloride and metformin hydrochloride in combination on the basis of diet control and exercise, or for type 2 diabetes patients whose blood sugar control is not satisfactory after treatment with metformin hydrochloride alone.
Beijing Beilu Pharmaceutical (300016.SZ) announced that the company has received the "Drug Registration Certificate" issued by the National Medical Products Administration for the Pioglitazone Metformin Tablets (15mg/500mg). This product is suitable for type 2 diabetes patients who are currently using Pioglitazone Hydrochloride and Metformin Hydrochloride in combination therapy on the basis of diet control and exercise, or for type 2 diabetes patients who have poor blood sugar control after treatment with Metformin Hydrochloride alone.
Related Articles
COURAGE INV has appointed Ernst & Young as its new auditor.
Youcare Pharmaceutical Group (688658.SH): YKYY031 for injection has received approval to conduct clinical trials for advanced solid tumors.
Vitasoy International (00345) spent HK$13,300 to repurchase 2000 shares on December 12th.
COURAGE INV has appointed Ernst & Young as its new auditor.
Youcare Pharmaceutical Group (688658.SH): YKYY031 for injection has received approval to conduct clinical trials for advanced solid tumors.
Vitasoy International (00345) spent HK$13,300 to repurchase 2000 shares on December 12th.
